Cannabis breeding is entering a new chapter—one that moves beyond the dominance of THC and CBD toward a nuanced spectrum of minor cannabinoids. Among the most intriguing of these are tetrahydrocannabivarin (THCV) and cannabigerol (CBG). While both are rare in most strains, breeders are beginning to imagine a future where cultivars consistently express high levels of both, offering unique therapeutic and lifestyle benefits.

The Allure of THCV

THCV has earned the nickname “the diet weed,” though its potential extends far beyond appetite control. Its propyl side chain distinguishes it from THC and accounts for very different pharmacological effects. In low doses, THCV is non-intoxicating and may even counteract some of THC’s psychoactivity. Research suggests it can regulate blood sugar, support weight management, and provide a clear, focused mental state—qualities that make it appealing to patients and wellness-focused consumers alike.

Why CBG Matters

CBG, often called the “mother cannabinoid,” is the building block from which other cannabinoids are synthesized. While traditionally found only in trace amounts, selective breeding has yielded hemp varieties with 10–15% CBG content. It is associated with mood elevation, reduced anxiety, and potential neuroprotective qualities. Many users describe CBG as calming yet energizing—an attractive option for daytime use.

A Synergistic Potential

Pairing THCV’s energizing clarity with CBG’s balanced calm creates a cannabinoid profile that could stand apart in the marketplace. Instead of sedation or intense euphoria, such strains may deliver focus, mood support, and functional wellness benefits. Early attempts to bring this vision to life are already underway. For example, Emerald Spirit Botanicals developed “Trilogy,” a cultivar bred by crossing Pink Boost Goddess (high in THCV) with Equinox CBG. The result is a flower that regularly tests at 2–5% THCV, 2–5% CBG, and mid-teens THC, offering a layered, uplifting experience.

The Breeding Process

Achieving dual-high THCV and CBG expression is not simple. Breeders face the challenge of stabilizing uncommon cannabinoid pathways that often compete with one another. The process involves:

• Careful parent selection. Choosing one parent known for its THCV production (like Doug’s Varin or Pink Boost Goddess) and another with a strong CBG backbone (such as White CBG or Lemon Diesel CBG).
• Iterative crossbreeding. Breeders perform multiple generations of selection, keeping only plants that reliably show elevated levels of both cannabinoids.
• Backcrossing. By breeding offspring back with a parent strain, certain traits—such as THCV potency—can be reinforced without losing CBG expression.

The result is not just one lucky phenotype but a stabilized line capable of consistent cannabinoid output.

Where the Market Stands

Despite progress, high-THCV and high-CBG strains remain scarce. Most dispensary shelves still feature THC-dominant products, with CBD following as a distant second. Cultivars featuring significant levels of THCV or CBG are often limited releases or specialty items, reflecting the complexity of the breeding process and the relatively low demand—so far. Still, as consumers become more aware of the unique benefits these cannabinoids provide, the demand curve may shift dramatically.

The Road Ahead

The cannabis industry thrives on innovation, and dual-high THCV/CBG strains represent one of the most exciting frontiers. If researchers can further validate the therapeutic promise of these cannabinoids, and breeders can scale production, the market may soon see cultivars that redefine how consumers use cannabis—less for intoxication and more for clarity, productivity, and wellness.

For now, the science of crossbreeding continues, and with it, the possibility of strains that blend the rare with the practical. The fusion of THCV and CBG is not just about novelty; it’s about creating a cannabis experience designed for the future.

Discover THCV-Rich strains here.